Dáil Éireann Debate, Tuesday - 20 November 2018
415. Deputy James Browne asked the Minister for Health the number of the 48 recommendations of the national rare disease plan 2014-2018 that have been implemented; the recommendations that have not been implemented; and if he will make a statement on the matter. [47995/18]
View answerIn 2017, the Department published a progress report on the National Rare Disease Plan and this is available on the Department’s website at: http://health.gov.ie/blog/publications/interim-report-on-national-rare-disease-plan-for-ireland-2014-2018/. It provides an update on all 48 recommendations as outlined in the Plan and progress achieved.
One of the principal recommendations in the Plan was the establishment of a National Clinical Programme for Rare Diseases which is responsible for assisting with mapping and developing care pathways for rare diseases; facilitating timely access to centres of expertise, nationally and internationally; and developing care pathways with European Reference Centres for those ultra-rare disorders where there may not be sufficient expertise in Ireland.
In line with the National Rare Diseases Plan, the National Clinical Programme for Rare Diseases and the Department of Health encouraged designated centres of expertise in Ireland to apply for membership of European Reference Networks (ERNs) during the first round of calls from the European Commission for participation in ERNs. Membership of ERNs will bring opportunities for engaging in research relating to Rare Diseases in keeping with the National Rare Diseases Plan. Further centres are expected to apply for membership or affiliated membership of ERNs when the next call takes place.
The establishment of a National Rare Disease Office (NRDO) featured prominently in the recommendations of the Rare Disease plan. The office provides current and reliable information about rare diseases to the general public, health care professionals, researchers and policy makers. The National Rare Diseases Office is responsible for updating Orphanet Ireland. Orphanet is the international rare disease reference and information portal funded by the EU. The office also manages the National Rare Diseases Information Line (a Freephone service) and provides online information about rare diseases on http://www.rarediseases.ie/.
A number of recommendations about access to appropriate drugs and technologies were contained in the plan. One chief recommendation in this regard refers to the HSE developing a Working Group to bring forward appropriate decision criteria for the reimbursement of orphan medicines and technologies; and that the approach should include an assessment system similar to that for cancer therapies established under the National Cancer Control Programme. The HSE Acute Hospitals Division has developed the terms of reference, required membership and reporting relationship for this committee and Dr Michael Barry has been appointed as committee chairperson. A first meeting has taken place and membership of the Committee includes two public/patient representatives from a selected panel of three. The Rare Diseases Medicinal Products/Technology Review Committee is responsible for:
1. Reviewing proposals received from industry or expert groups in Ireland for funding of new products for rare diseases, or expanded indications for existing products for rare diseases and making recommendations as to the implementation of the relevant recommendations from the National Rare Diseases Plan 2011-2018; and
2. Providing contributions to the development of clinical guidelines for relevant Orphan Medicinal Products (OMPs) and supporting the implementation of guidelines in conjunction with the National Drugs Management Programme Office where applicable.
This Committee will also be supported by the National Clinical Programme for Rare Diseases Clinical Advisory Group.
The national plan for rare diseases recommended that the Health Identifiers Bill and the Health & Patient Safety Bill be published. The former was published in 2013 and enacted in 2014. The Individual Health Identifier part of the project is now being implemented by the HSE. The Patient Safety Bill 2018 is available on the Department’s website: https://health.gov.ie/blog/publications/general-scheme-patient-safety-bill-5-july-2018/.
Two recommendations referred to training in rare diseases for healthcare professionals. The Department of Health has contacted formally the various healthcare representative and professional bodies about implementing these recommendations. The National Rare Diseases Office developed eLearning modules for healthcare professionals. These modules are available on: http://www.hse.ie/eng/services/list/5/rarediseases/healthcareprofessionals.html.
The issue of rare diseases and of the creation of an all-island patient register has been raised in the context of on-going discussions at North-South meetings. It is also anticipated that the Model of Care for Rare Diseases will set out recommendations for rare disease registries. A public consultation was held on the Draft Model of Care, the results of which are currently under consideration.
The National Clinical Programme has developed a Model of Care for Transition from Paediatric to Adult Healthcare Providers in Rare Diseases. This has been now finalised and approved by the Clinical Advisory Group.
The National Rare Disease Plan continues to be implemented. It recommended that an Oversight Implementation Group of relevant stakeholders, including patients' groups, be established to oversee and monitor implementation of the plan’s recommendations. This group was established by the Department of Health in 2015 and has met on a number of occasions.
While the current National Rare Disease Plan for Ireland will continue to be implemented, as part of its Work Programme for 2019 my Department is considering how best to take forward the next phase of the Plan.
